Cidara Therapeutics, Inc. Cashflow Statement

Ask AI

Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Consolidated Statements of Cash Flows

In millions of USD, except per-share amounts

	FY2024 12 months to Dec 31, 2024	FY2023 12 months to Dec 31, 2023	FY2022 12 months to Dec 31, 2022	FY2021 12 months to Dec 31, 2021	FY2020 12 months to Dec 31, 2020
Operating activities:
Net loss
Adjustments to reconcile net loss to net cash used in operating activities:
Loss on disposal of discontinued operations
Stock-based compensation
Non-cash operating lease expense
Deferred rent
Change in fair value of contingent forward purchase obligations
Contingent forward purchase obligation offering costs
Depreciation and amortization
Amortization of costs to obtain a contract with a customer
Amortization of finance lease right-of-use asset
Non-cash interest expense
Amortization of discount or premium on short-term investments
Amortization of debt issuance costs
Changes in assets and liabilities:
Accounts receivable
Inventory
Prepaid expenses, other current assets, and other assets
Accounts payable and accrued liabilities
Accrued indirect tax liabilities
Accrued compensation and benefits
Deferred revenue
Contract liabilities
Operating lease liabilities
Other assets

Net cash used in operating activities
Investing activities:
Purchases of short-term investments
Maturities of short-term investments
Purchases of property and equipment
Net cash used in investing activities

Financing activities:
Proceeds from Registered Direct Offering, net of offering costs
Proceeds from private placements, net of issuance costs
Proceeds from underwritten public offering, net of issuance costs
Series X Convertible Preferred Stock
Stock Purchase Agreement
Total proceeds from underwritten public offering, net of issuance costs

Proceeds from issuance of Common and Series X Preferred pursuant to rights offering, net of issuance costs.
Proceeds from public offering of common stock, net of issuance costs
Proceeds from exercise of stock options
Issuance costs for underwritten public offering
Principal repayments of Term Loan
Payment of finance lease liabilities
Payment for shares withheld to fund payroll taxes
Net cash provided by financing activities

Net increase in cash, cash equivalents and restricted cash
Cash, cash equivalents and restricted cash at beginning of year
Cash, cash equivalents and restricted cash at end of year
Supplemental disclosure of cash flows:
Interest paid
Income taxes paid
Non-cash investing activities:
Purchases of property and equipment, included in accounts payable and accrued liabilities
Finance lease right-of-use asset obtained in exchange for lease liability
Operating lease right-of-use asset obtained in exchange for lease liability
Non-cash financing activities:
Purchase of shares pursuant to Employee Stock Purchase Plan
Vesting of early exercised stock options
Proceeds from public offering of common stock, net of issuance costs, included in prepaid expenses and other current assets
Proceeds from public offering of common stock, net of issuance costs, included in prepaid expenses, other current assets, and other assets
Proceeds from exercise of stock options included in prepaid expenses, other current assets, and other assets

Comments